Circulating cardiovascular biomarkers in motion: redefining cardiovascular risk with dynamic prediction - Top-Institutions - MDSpire

Circulating cardiovascular biomarkers in motion: redefining cardiovascular risk with dynamic prediction

  • By

  • Marie de Bakker

  • Becky Gordon

  • Anoop S V Shah

  • Eric Boersma

  • Dorien M Kimenai

  • December 8, 2025

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Framingham Heart Study, Boston University
    Framingham Heart Study, Boston University

    Boston, MA

    Key Differentiators

    • Cardiology
    • Epidemiology
    • Biostatistics

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Cardiology
    • Preventive Medicine
    • Clinical Epidemiology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Cardiology
    • Translational Research
    • Biomarker Discovery

  • #4

    Harvard T.H. Chan School of Public Health
    Harvard T.H. Chan School of Public Health

    Boston, MA

    Key Differentiators

    • Epidemiology
    • Public Health
    • Cardiovascular Research

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Cardiology
    • Clinical Research
    • Biostatistics

Original Source(s)

Circulating cardiovascular biomarkers in motion: redefining cardiovascular risk with dynamic prediction

  • by Marie de Bakker, Becky Gordon, Anoop S V Shah, Eric Boersma, Dorien M Kimenai

  • December 8, 2025

Related Content

Validation of 2 Syncope Risk Scores and Comparison With Physician Risk Estimation

Correction: Multicriteria Optimization of Language Models for Heart Failure With Preserved Ejection Fraction Symptom Detection in Spanish Electronic Health Records: Comparative Modeling Study

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.